Standard of care for cancer screening: the term implies certainty and consensus. Physicians, patients, and organizations have created guidelines, policies, and regulations regarding how, when, and for whom screening should be used or reimbursed; cumulatively, these statements become the standards of care. However, these standards vary markedly across organ type, often without rationale or evidence.
In this Viewpoint, we highlight 3 areas in which cancer screening standards differ markedly for breast, colorectal, and cervical cancer: funding, quality measures, and reporting. These variations were delineated through a cross-disciplinary collaboration among scientists, health care organizations, and society leaders within the National Cancer Institute’s (NCI’s) Population-Based Research Optimizing Screening Through Personalized Regimens (PROSPR) consortium.1 PROSPR studies how breast, cervical, and colorectal cancer screening is implemented in diverse, real-world settings.
Douglas A. Corley, Jennifer S. Haas, Sarah Kobrin. Reducing Variation in the “Standard of Care” for Cancer ScreeningRecommendations From the PROSPR Consortium. JAMA. 2016;315(19):2067–2068. doi:10.1001/jama.2016.3067
* * Maintenance Notice * *
Maintenance will be performed from 11:00pm CT December 16, 2017 to 4:00pm CT December 17. Please be advised that your site/services may be periodically unavailable during this maintenance window.